How academic researchers, industry
and patients collaborate in order to fight Type 1 Diabetes.
INNODIA is a global partnership between 31 academic institutions, 6 industrial partners, a small sized enterprise and 2 patient organizations, bringing their knowledge and experience together with one common goal: "To fight type 1 diabetes".
The project runs under the framework of the Innovative Medicines Initiative – Joint Undertaking (IMI-JU) with a dedicated governance structure ensuring close interaction, communication and adherence to the objectives and deliverables of the consortium. Importantly, INNODIA is closely guided by the patients themselves, through the Patient Advisory Committee, consisting of a group of type 1 diabetes patients and parents, which give continuous feedback on the concept of INNODIA and development of protocols, and are crucial in disseminating the goals of INNODIA to the public.
INNODIA collects throughout Europe blood samples and data from newly diagnosed patients with type 1 diabetes and their first degree relatives. With these data we can study the evolution of the disease in these individuals and develop new ways to predict the risk for relatives for developing the disease and eventually find a cure for those already diagnosed with the disease.
Novel research tools, making use of advanced technologies, already available or under development in the different academic partner institutes and pharmaceutical company, are being applied and aim to result in the identification of new disease biomarkers to predict the individual risk for relatives to develop the disease. Also, these biomarkers, which are factors that can be measured in the blood of each individual, may lead to the design of better and more personalized therapies.
Thanks to the INNODIA research we will be able to better understand the relationship between changes in β-cell function, immune profiles, genetic and environmental factors and their role in the onset of the disease.
A second major goal of INNODIA is to perform the clinical intervention studies VER-A-T1D, MELD-ATG, CFZ533 and IMPACT, that have started in 2020. Here again, pharmaceutical companies being part of INNODIA join forces with leading academic clinical researchers to prove the effectiveness of these potential new therapeutic agents.
Newly diagnosed type 1 diabetic patients and their relatives are encouraged to participate in this study by contacting one of our Clinical Centers throughout Europe. If you like to take part in this initiative, please consult our map to select a Center most nearby and complete the registration form so we can contact you.
The Innovative Medicines Initiative (IMI) initiated by the European Commission has approved an additional section of work on biomarkers and prevention of type 1 diabetes within INNODIA. This additional section builds on the strong base of INNODIA and will be called INNODIA HARVEST. INNODIA has developed a unique European clinical and fundamental research network for the study of type 1 diabetes (T1D). An additional, even more ambitious program is now being proposed in this research network, aimed at 'harvesting' the findings that have already arisen from INNODIA.
Consolidation and innovation are key words.
First, the INNODIA Clinical Network consolidates as a pan-European reference point for conducting studies to prevent or cure T1D. Standardized clinical and bio-research platforms built in INNODIA are upgraded into a powerful network allowing us to conduct clinical trials aimed at preventing and curing T1D. These trials can be both academic and industry sponsored. We are performing smaller, mechanistic, biomarker-rich intervention tests to better understand the development of T1D. Several large studies are underway in the network, notably the MELD-ATG trial (seeking the lowest, safest dose of anti-thymocyte globulin, a Sanofi product, in children with newly-diagnosed T1D), the VER-A-T1D trial (investigating whether verapamil in adults with newly diagnosed T1D can stop disease progression), the Iscalimab study (study investigating children with newly diagnosed T1D or Iscalimab, a Novartis product can safely stop disease progression). In addition, Imcyse, a small Belgian company, a member of the network is testing its new "Immotope" technology in a small mechanistic study.
The second key word of INNODIA HARVEST is innovation. The network is operating based on the INNODIA Master Protocol, allowing different interventions to be compared. Another innovation is the introduction of new (discovered by the network) biomarkers as well as new clinical (continuous glucose monitoring) and experimental (microbiome analysis) markers, in order to better understand the heterogeneity of T1D and thus lead to faster healing strategies. Furthermore, the basic research of INNODIA's group of researchers is flowing further into INNODIA HARVEST to promote the next generation of target identification and drug development.
Finally, as in INNODIA, the voice of people living with T1D and their families remains at the center of INNODIA HARVEST to drive the implementation of new, patient-centered results, shape our clinical trials and make a meaningful change in the disease perspective.